Tremelimumab trial discontinued
Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy.
NEW YORK-Pfizer Inc has discontinued a phase III trial of single-agent tremelimumab in patients with advanced melanoma after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy. “We will continue to assess the study data to understand the clinical benefit seen in some patients who received tremelimumab,” said Pfizer’s Charles Baum, MD, PhD.
Articles in this issue
Proton therapy training offered
Editor of Blood reviews a very bloody movie
Artists take note: Oncology on Canvas accepting entries
PET affects treatment in over one-third of cancer cases
Expanded use of Axxent approved
Gardasil supplemental application gets priority review designation
Optical tomo/US monitors adjuvant chemo response
GIST patients resistant to imatinib/sunitinib respond to sorafenib
Sunitinib plus a taxane active in advanced breast cancer
Stanford V yields excellent outcomes in bulky, advanced HL
Monica Morrow joins Memorial Sloan-Kettering Cancer Center
Nereus initiates phase 1b trial of NPI-2358 in NSCLC patients
LHRH agonist use declines after reimbursement cuts
Palliative care helps pediatric pts at end of life
New colon screening guideline includes CT colonography
Recent Videos
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
